Valeant Pharmaceuticals Intl Inc (VRX) Director Purchases C$70,315.00 in Stock
Valeant Pharmaceuticals Intl Inc (TSE:VRX) (NYSE:VRX) Director Schutter Richard Urbain De bought 4,900 shares of Valeant Pharmaceuticals Intl stock in a transaction that occurred on Monday, August 21st. The shares were acquired at an average cost of C$14.35 per share, with a total value of C$70,315.00.
Valeant Pharmaceuticals Intl Inc (TSE VRX) traded down 4.45% on Friday, reaching $17.62. 1,440,357 shares of the company’s stock were exchanged. The company’s market capitalization is $6.14 billion. The firm has a 50-day moving average price of $20.01 and a 200-day moving average price of $17.58. Valeant Pharmaceuticals Intl Inc has a 1-year low of $11.20 and a 1-year high of $40.68.
TRADEMARK VIOLATION WARNING: This report was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://theolympiareport.com/2017/08/27/valeant-pharmaceuticals-intl-inc-vrx-director-purchases-c70315-00-in-stock.html.
Several brokerages recently issued reports on VRX. Royal Bank Of Canada reissued a “sector perform” rating and set a C$25.00 target price on shares of Valeant Pharmaceuticals Intl in a report on Monday, June 19th. Cantor Fitzgerald reissued an “overweight” rating on shares of Valeant Pharmaceuticals Intl in a report on Thursday, June 29th. Scotiabank raised their target price on shares of Valeant Pharmaceuticals Intl to C$19.00 and gave the stock a “sector perform” rating in a report on Wednesday, May 10th. Finally, TD Securities reduced their target price on shares of Valeant Pharmaceuticals Intl to C$20.50 and set a “hold” rating for the company in a report on Wednesday, May 10th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of C$23.33.
Valeant Pharmaceuticals Intl Company Profile
Valeant Pharmaceuticals International, Inc operates as a pharmaceutical and medical device company worldwide. It operates in three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The company offers Lotemax gel for the treatment of inflammation and pain following ocular surgery; Ocuvite, a lutein eye vitamin and mineral supplement; PreserVision, an antioxidant eye vitamin and mineral supplement; ReNu Multiplus products; Biotrue multi-purpose solution for healthy contact lens wear; Artelac to treat dry eyes; Boston, a cleansing solution for gas permeable contact lenses; and Bedoyecta, a vitamin B complex.
Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.